AstraZeneca (LON:AZN) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Shares of AstraZeneca PLC (LON:AZN) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of £135.74 and traded as high as £154.32. AstraZeneca shares last traded at £153.16, with a volume of 2,036,970 shares trading hands.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AZN shares. Shore Capital Group restated a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. Citigroup began coverage on shares of AstraZeneca in a research report on Tuesday, January 27th. They issued a “buy” rating and a £170 price objective on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research note on Thursday, January 15th. Berenberg Bank raised their target price on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a research note on Tuesday, January 27th. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of £145.83.

AstraZeneca Stock Up 2.0%

The company has a debt-to-equity ratio of 60.87, a quick ratio of 0.59 and a current ratio of 0.94. The firm has a market capitalization of £237.51 billion, a price-to-earnings ratio of 23.42, a PEG ratio of 0.86 and a beta of 0.23. The firm has a fifty day moving average price of £145.02 and a 200 day moving average price of £135.74.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.